ArticleTherapeutic advances in medical oncology2025
Immune checkpoint inhibitors improve the efficacy of neoadjuvant chemotherapy in advanced gastric cancer: a retrospective cohort study.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Perioperative Chemoimmunotherapy vs. Chemotherapy Alone for Gastroesophageal Cancer: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Modulation of the gut microbiota by traditional Chinese medicine to attenuate chemotherapy-induced toxicity in gastric cancer: a review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Precision oncology in gastric cancer: navigating molecular subtypes, therapeutic targets, and future horizons.Cellular oncology (Dordrecht, Netherlands) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in metastatic gastric cancer. Their potential benefits in the neoadjuvant therapy for advanced gastric cancer (AGC) are promising but require real-world evidence. Objective: We aimed to assess the real-world impact of adding ICIs to neoadjuvant chemotherapy (NAC) in AGC patients. Design: This is a retrospective, propensity score-matched analysis of 580 AGC patients treated with NAC, with or without ICIs, followed by radical gastrectomy. Methods: Patients were matched using propensity score matching (PSM) to balance baseline characteristics. Pathological complete response (pCR) rates and toxicity were compared between the ICIs-Chemo and Chemo cohorts. Results: After PSM, 188 patients were included: 71 in the ICIs-Chemo cohort and 117 in the Chemo cohort. Chemotherapy regimens in both cohorts included SOX (49.5%, 93/188), FLOT (26.6%, 50/188), XELOX (12.8%, 24/188), and FOLFOX (11.2%, 21/188). The ICIs used were predominantly Sintilimab (67.6%, 48/71), followed by Tislelizumab (21.1%, 15/71), Nivolumab (7%, 5/71), and others (4.2%, 3/71). Adding ICIs to NAC significantly improved the pCR rate (ICIs-Chemo: 29.6% vs. Chemo: 13.7%, Conclusion: Adding ICIs to NAC regimens in AGC significantly improves pathological response. While overall toxicity is not increased, close monitoring for irAEs is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.